NEW YORK (GenomeWeb) – The US Food and Drug Administration this week granted breakthrough therapy status to Genentech's anti-PD-L1 cancer immunotherapy MPDL3280A as a treatment for NSCLC patients who have progressed despite treatment with platinum-based chemotherapy and targeted therapy.

In clinical trials for the drug, Genentech is characterizing the PD-L1 expression status of non-small cell lung cancer patients using an immunohistochemistry test developed by parent firm Roche.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jun
26
Sponsored by
Lexogen

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.